Defibrotide
- Generic Name
- Defibrotide
- Brand Names
- Defitelio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83712-60-1
- Unique Ingredient Identifier
- 568FY5I1YI
- Background
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a...
- Indication
Indicated for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).
- Associated Conditions
- Sinusoidal Obstruction Syndrome (SOS)
- Associated Therapies
- -
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 151
- Registration Number
- NCT00003966
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.